Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Rush to Comparative Effectiveness: FDA's Woodcock Hopes It Won't Overshadow Personalized Medicine

This article was originally published in RPM Report

Executive Summary

Comparative effectiveness research is a central theme of the Obama Administration's health reform effort. But as the debate heats up on Capitol Hill, one top FDA official, Janet Woodcock, doesn't want to lose sight of an increasingly important drug development strategy: personalized medicine.

You may also be interested in...



FDA and Health Care Reform: An Activist Agenda for the Agency

Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.

Comparative Effectiveness: Knowledge Not Coverage

The health industry's trade association supports a more formal and expanded federal comparative effectiveness research effort, with one caveat: the effort must be devoted to collecting and disseminating informaiton and not be tied directly to coverae or payment decisions. That aligns the health plans with Senate Finance Committee Chairman Max Baucus and creates a potent base for getting comparative effectiveness into upcoming health reform efforts.

The Next Steps for Personalized Health Care: Incentivizing Product Development

Roche has positioned itself as a leader in the development of more "personalized" health care products. What's needed now, CEO Abercrombie says, is a commitment from FDA to develop consistent approval standards and from CMS to guarantee coverage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel